Article PDF first page preview

First page of Efficacy of Vonoprazan-Based Triple Therapy with Sitafloxacin and Amoxicillin for Third-Line Helicobacter pylori Eradication: A Multicenter Prospective Analysis on Drug Resistance and gyrA Mutations

Introduction: Vonoprazan (VPZ) is a potent gastric acid secretion inhibitor used to improve the outcomes of Helicobacter pylori eradication treatments. However, the increasing prevalence of antibiotic-resistant H. pylori strains has limited the efficacy of H. pylori eradication therapies. The aim of this study was to evaluate the efficacy and safety of a 7-day triple therapy with VPZ, amoxicillin (AMOX), and sitafloxacin (STFX) as a third-line H. pylori eradication treatment. Methods: Patients in whom second-line eradication therapy failed were enrolled. The minimum inhibitory concentrations of STFX and AMOX, as well as the gyrA mutation status of H. pylori strains, were determined before treatment. The patients received VPZ (20 mg) twice daily, AMOX (500 mg) four times daily, and STFX (100 mg) twice daily for 7 days (vonoprazan-amoxicillin-sitafloxacin [VAS] group). Successful eradication was evaluated using the 13C urea breath test. Results: Of the 114 patients enrolled, 75 were treated with the VAS regimen. The overall eradication rate in the VAS group was 90.7% and 94.4% in the intention-to-treat and per-protocol populations, respectively. The VAS regimen completely eradicated GyrA mutation-negative H. pylori strains. Furthermore, it eradicated all strains containing gyrA mutations at position D91. Adverse events were observed in 38.7% of patients, and treatment was discontinued in one patient because of eruption, diarrhea, and headache. Conclusion: Overall, the 7-day VAS regimen exhibited excellent safety profile and efficacy as a third-line eradication treatment, even against gyrA mutation-positive H. pylori strains.

Journal Section:
Stomach and Duodenum
This content is only available via PDF.
S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2025
You do not currently have access to this content.